GE HealthCare Stock: Analyst Estimates & Ratings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2025
0mins
Should l Buy GEHC?
Source: NASDAQ.COM
Company Performance: GE HealthCare Technologies Inc. has a market cap of $32 billion but has underperformed the market, with stock prices declining 11.1% over the past year compared to the S&P 500's gains. Despite this, the company reported a 2.7% increase in Q1 revenue and a 12.3% rise in adjusted net income, surpassing analysts' expectations.
Analyst Ratings: The consensus rating for GEHC is "Strong Buy," with 13 out of 18 analysts recommending it as such. However, Morgan Stanley has maintained a "Hold" rating while lowering its price target, indicating mixed sentiments about the stock's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 79.200
Low
80.00
Averages
92.25
High
105.00
Current: 79.200
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GE HealthCare Technologies Declares Quarterly Dividend
- Quarterly Dividend Announcement: GE HealthCare Technologies has declared a quarterly dividend of $0.035 per share, payable on May 15, reflecting the company's stable cash flow and commitment to shareholder returns.
- Record Date for Shareholders: The record date for this dividend is April 3, with the ex-dividend date also set for April 3, ensuring eligible shareholders receive their dividends promptly, which enhances investor confidence.
- Future Growth Expectations: GE HealthCare anticipates an 8% to 12% growth in EPS for 2026, alongside a target of $1.7 billion in free cash flow, indicating strong potential driven by new product launches.
- Positive Market Reaction: Following fourth-quarter results that exceeded expectations, GE HealthCare's stock price has risen, reflecting market optimism regarding the company's future growth prospects and further solidifying its competitive position in the healthcare technology sector.
See More
GE HealthCare Declares Q1 2026 Cash Dividend
- Dividend Declaration: GE HealthCare's Board of Directors has declared a cash dividend of $0.035 per share for Q1 2026, payable on May 15, 2026, to all shareholders of record as of April 3, 2026, aimed at enhancing investor confidence and rewarding shareholders.
- Company Overview: GE HealthCare is a leading global provider of healthcare solutions, focusing on advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions, demonstrating strong market competitiveness in addressing complex diseases.
- Business Scale: With annual revenues of $20.6 billion and approximately 54,000 employees, GE HealthCare holds a significant position in the global healthcare industry, driving innovations that promote personalized and precise patient care.
- Industry Recognition: GE HealthCare has been named one of Fortune's Most Admired Companies for 2026, reflecting its strong reputation and ongoing innovation capabilities within the industry, further solidifying its market leadership.
See More
GE HealthCare Declares Q1 2026 Cash Dividend
- Dividend Declaration: GE HealthCare's Board of Directors has declared a cash dividend of $0.035 per share for Q1 2026, payable on May 15, 2026, reflecting the company's commitment to shareholder returns and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for April 3, 2026, ensuring that all eligible shareholders will receive the dividend, thereby strengthening the relationship between the company and its investors.
- Company Overview: GE HealthCare is a leading global provider of healthcare solutions, focusing on advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions, aimed at helping clinicians tackle complex diseases, showcasing its strong market competitiveness.
- Business Scale and Impact: With an annual revenue of $20.6 billion and approximately 54,000 employees, GE HealthCare continues to drive medical innovation, aiming to provide more personalized and precise patient care, demonstrating its leadership position in the healthcare industry.
See More
GE HealthCare Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: GE HealthCare will participate in Citi's and Barclays' MedTech investor conferences on February 26 and March 10, 2026, respectively, showcasing its leadership in medical technology and likely attracting investor interest to boost market confidence.
- Webcast Availability: Each event will feature a webcast accessible via the GE HealthCare website, ensuring global investors can stay updated on the company's latest developments, thereby enhancing transparency and investor relations.
- Company Background: GE HealthCare is a leading global healthcare solutions provider focused on advanced medical technology and AI solutions, dedicated to helping clinicians tackle complex diseases, with a business scale of $20.6 billion and approximately 54,000 employees, demonstrating strong market competitiveness.
- Industry Recognition: GE HealthCare has been named one of Fortune's Most Admired Companies for 2026, further solidifying its reputation in the healthcare industry and indicating the company's ongoing commitment to innovation and customer service.
See More
Texas Instruments Acquires Silicon Labs in $7.5B Deal
- Acquisition Agreement: Texas Instruments is set to acquire Silicon Labs for $231 per share in an all-cash transaction valued at $7.5 billion, which not only boosts Silicon Labs' market valuation but also enhances Texas Instruments' competitive edge in the semiconductor sector.
- Positive Market Reaction: Following the acquisition announcement, Silicon Labs' stock surged by 49%, indicating strong investor confidence in the deal and reflecting optimistic expectations for consolidation within the semiconductor industry.
- Strong Earnings Performance: Silicon Labs reported an adjusted EPS of 56 cents for Q4, slightly above the consensus estimate of 55 cents, demonstrating stable financial performance that enhances the attractiveness of the acquisition.
- Industry Consolidation Trend: This acquisition represents a strategic move for Texas Instruments to expand its product line and signifies an acceleration in semiconductor industry consolidation, potentially triggering more similar deals that could reshape the market landscape.
See More
GE HealthCare Technologies Q4 2025 Earnings Highlights
- Strong Financial Performance: GE HealthCare reported Q4 2025 revenue of $5.7 billion, reflecting a 4.8% year-over-year organic growth that exceeded expectations, showcasing robust demand in pharmaceutical diagnostics and enhancing market competitiveness.
- Acquisition Plans and Growth Outlook: The planned acquisition of Intelerad is projected to add $270 million in annual revenue, accelerating the company's cloud-first imaging ecosystem and enhancing its recurring revenue stream, which is strategically significant for long-term growth.
- Product Launches and Innovation: The commercial availability of Omni total body PET and next-generation SPECT in Europe is expected to drive future order growth, with management reporting a strong three-year vitality rate of 55% for new products, up 5% from the previous year, indicating strong market demand.
- Future Outlook and Risk Management: Management anticipates organic revenue growth of 3% to 4% for 2026, maintaining a cautious outlook for the Chinese market; however, a robust pipeline of new product innovations is expected to support future growth despite challenges.
See More
GE HealthCare Technologies Declares Quarterly Dividend
- Quarterly Dividend Announcement: GE HealthCare Technologies has declared a quarterly dividend of $0.035 per share, payable on May 15, reflecting the company's stable cash flow and commitment to shareholder returns.
- Record Date for Shareholders: The record date for this dividend is April 3, with the ex-dividend date also set for April 3, ensuring eligible shareholders receive their dividends promptly, which enhances investor confidence.
- Future Growth Expectations: GE HealthCare anticipates an 8% to 12% growth in EPS for 2026, alongside a target of $1.7 billion in free cash flow, indicating strong potential driven by new product launches.
- Positive Market Reaction: Following fourth-quarter results that exceeded expectations, GE HealthCare's stock price has risen, reflecting market optimism regarding the company's future growth prospects and further solidifying its competitive position in the healthcare technology sector.
See More
GE HealthCare Declares Q1 2026 Cash Dividend
- Dividend Declaration: GE HealthCare's Board of Directors has declared a cash dividend of $0.035 per share for Q1 2026, payable on May 15, 2026, to all shareholders of record as of April 3, 2026, aimed at enhancing investor confidence and rewarding shareholders.
- Company Overview: GE HealthCare is a leading global provider of healthcare solutions, focusing on advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions, demonstrating strong market competitiveness in addressing complex diseases.
- Business Scale: With annual revenues of $20.6 billion and approximately 54,000 employees, GE HealthCare holds a significant position in the global healthcare industry, driving innovations that promote personalized and precise patient care.
- Industry Recognition: GE HealthCare has been named one of Fortune's Most Admired Companies for 2026, reflecting its strong reputation and ongoing innovation capabilities within the industry, further solidifying its market leadership.
See More
GE HealthCare Declares Q1 2026 Cash Dividend
- Dividend Declaration: GE HealthCare's Board of Directors has declared a cash dividend of $0.035 per share for Q1 2026, payable on May 15, 2026, reflecting the company's commitment to shareholder returns and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for April 3, 2026, ensuring that all eligible shareholders will receive the dividend, thereby strengthening the relationship between the company and its investors.
- Company Overview: GE HealthCare is a leading global provider of healthcare solutions, focusing on advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions, aimed at helping clinicians tackle complex diseases, showcasing its strong market competitiveness.
- Business Scale and Impact: With an annual revenue of $20.6 billion and approximately 54,000 employees, GE HealthCare continues to drive medical innovation, aiming to provide more personalized and precise patient care, demonstrating its leadership position in the healthcare industry.
See More
GE HealthCare Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: GE HealthCare will participate in Citi's and Barclays' MedTech investor conferences on February 26 and March 10, 2026, respectively, showcasing its leadership in medical technology and likely attracting investor interest to boost market confidence.
- Webcast Availability: Each event will feature a webcast accessible via the GE HealthCare website, ensuring global investors can stay updated on the company's latest developments, thereby enhancing transparency and investor relations.
- Company Background: GE HealthCare is a leading global healthcare solutions provider focused on advanced medical technology and AI solutions, dedicated to helping clinicians tackle complex diseases, with a business scale of $20.6 billion and approximately 54,000 employees, demonstrating strong market competitiveness.
- Industry Recognition: GE HealthCare has been named one of Fortune's Most Admired Companies for 2026, further solidifying its reputation in the healthcare industry and indicating the company's ongoing commitment to innovation and customer service.
See More
Texas Instruments Acquires Silicon Labs in $7.5B Deal
- Acquisition Agreement: Texas Instruments is set to acquire Silicon Labs for $231 per share in an all-cash transaction valued at $7.5 billion, which not only boosts Silicon Labs' market valuation but also enhances Texas Instruments' competitive edge in the semiconductor sector.
- Positive Market Reaction: Following the acquisition announcement, Silicon Labs' stock surged by 49%, indicating strong investor confidence in the deal and reflecting optimistic expectations for consolidation within the semiconductor industry.
- Strong Earnings Performance: Silicon Labs reported an adjusted EPS of 56 cents for Q4, slightly above the consensus estimate of 55 cents, demonstrating stable financial performance that enhances the attractiveness of the acquisition.
- Industry Consolidation Trend: This acquisition represents a strategic move for Texas Instruments to expand its product line and signifies an acceleration in semiconductor industry consolidation, potentially triggering more similar deals that could reshape the market landscape.
See More
GE HealthCare Technologies Q4 2025 Earnings Highlights
- Strong Financial Performance: GE HealthCare reported Q4 2025 revenue of $5.7 billion, reflecting a 4.8% year-over-year organic growth that exceeded expectations, showcasing robust demand in pharmaceutical diagnostics and enhancing market competitiveness.
- Acquisition Plans and Growth Outlook: The planned acquisition of Intelerad is projected to add $270 million in annual revenue, accelerating the company's cloud-first imaging ecosystem and enhancing its recurring revenue stream, which is strategically significant for long-term growth.
- Product Launches and Innovation: The commercial availability of Omni total body PET and next-generation SPECT in Europe is expected to drive future order growth, with management reporting a strong three-year vitality rate of 55% for new products, up 5% from the previous year, indicating strong market demand.
- Future Outlook and Risk Management: Management anticipates organic revenue growth of 3% to 4% for 2026, maintaining a cautious outlook for the Chinese market; however, a robust pipeline of new product innovations is expected to support future growth despite challenges.
See More
